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A major safety concern with the use of herbal medicinal products (HMP) is their interactions with conventional medicines,
which are often mediated via the cytochrome P450 (CYP) system. Echinacea is a widely used over-the-counter HMP, with proven
immunomodulatory properties. Its increasing use makes research into its safety an urgent concern. Previously, we showed that
Echinacea extracts and its alkylamides (thought to be important for Echinacea’s immunomodulatory activity) mildly inhibit
the enzymatic activity of the main drug metabolising CYP isoforms, but to this date, there is insuﬃcient work on its ability to
alter CYP expression levels. We now report for the ﬁrst time the eﬀect of a commercial Echinacea extract (Echinaforce) and four
Echinacea alkylamides on the transcription of the major drug metabolizing enzyme CYP3A4. HepG2 cells were exposed for 96
h to clinically relevant concentrations of Echinaforce (22, 11.6 and 1.16μgm L −1) or the alkylamides (1.62 and 44 nM). CYP3A4
mRNA levels were quantiﬁed using real-time reverse transcription polymerase chain reaction (RT-PCR). Neither Echinaforce nor
the alkylamides produced any signiﬁcant changes in the steady-state CYP3A4 mRNA levels, under these conditions. In contrast,
treatment with 50μM rifampicin resulted in a 3.8-fold up-regulation over the vehicle control. We conclude that Echinaforce is
unlikely to aﬀect CYP3A4 transcriptional levels, even at concentrations which can inhibit the enzymatic activity of CYP3A4.
Overall, our data provides further evidence for the lack of interactions between Echinacea and conventional drugs.
1.Introduction
Interactions between herbal medicinal products (HMP) and
conventional drugs are a major safety concern. One of the
main pathways for such interactions is via the cytochrome
P450 (CYP) enzymes. Direct inhibition or induction of CYP
isoforms by HMP can alter the metabolism of conventional
drugs, leading to adverse eﬀects. An example showcasing the
signiﬁcance of such interactions is St. John’s Wort, which
has been shown to aﬀect the pharmacokinetics of several
important drugs [1], highlighting the need for in vitro
investigations into the possible interactions of HMP with
CYP isoforms [2].
EchinaceaisapopularHMP,wellknownforitsimmuno-
modulatorypropertiesandusedworldwideforthetreatment
of upper respiratory tract infections [3–5]. Previously, we
investigated in detail the ability of Echinacea to inhibit
various CYP isoforms [6]. We showed that Echinacea and
some of its alkylamides weakly inhibit a number of major
CYP isoforms. We also screened 10 commercially available
Echinacea liquid preparations (ELP) for CYP3A4 inhibitory
activity and found that it varied considerably (IC50 values
12.7–1817μgmL −1)[ 6].
Aside from direct enzymatic inhibition, HMPs can
aﬀect CYP activity by altering their transcriptional activity
(i.e., induce or suppress CYP expression). Altering CYP
expression will aﬀect drug metabolism in three diﬀerent
ways. It can alter drug elimination, pro-drug activation, or
drug bioactivation (i.e., conversion to toxic metabolites), all
of which can have serious consequences [7, 8].
CYP gene induction may occur via the action of three
intracellular receptors: the aryl hydrocarbon receptor (AhR),2 Evidence-Based Complementary and Alternative Medicine
theconstitutiveandrostanereceptor(CAR)andthepregnane
Xr e c e p t o r( P X R )[ 7, 8]. PXR is believed to be the main
mediator of CYP3A gene induction [7]. The mechanism of
CYP induction is shown in Figure 1. An important example
of CYP induction by HMP is St John’s Wort (Hypericum
perforatum), which has been shown to induce CYP3A4
through PXR activation and can signiﬁcantly decrease the
plasma concentration of concurrently used medicines (e.g.,
ciclosporin indinavir and the oral contraceptive) [9]. Other
natural products, which can induce CYP expression, include
kava kava (Piper methysticum G. Forster), used to treat
anxiety and Qing hao (Artemisia ammua) used traditionally
as an antipyretic [9].
To date, there is limited data on the induction of CYP
enzymes by ELP. Hellum and colleagues [10] found that a
commercial ELP (Echinagard-Madaus AG) moderately sup-
pressed CYP3A4 expression in primary human hepatocytes.
In addition, Gorski et al. [11] found that Echinacea could
causeinduction of CYP3A4 in intestinal cells, butsuppressed
hepatic CYP3A4 expression. Both authors directly assayed
CYP activity alone, not the protein or mRNA steady-state
levels and their results may be inﬂuenced by the presence of
various Echinacea constituents that can inhibit CYP activity.
Thus, the ability of Echinacea to induce CYP expression is
still not well described and a more detailed characterization
is needed.
We have carried out such an analysis of CYP3A4
induction in human hepatocellular carcinoma HepG2 cells
by an ELP (Echinaforce), using real-time reverse tran-
scription polymerase chain reaction (RT-PCR) to deter-
mine steady-state mRNA levels. In addition, since alky-
lamides are important both for the therapeutic activity
of Echinacea [12] and its CYP inhibitory potency [13],
we investigated whether the isolated alkylamides: dodeca-
2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide (i), dodeca-
2E,4E-dienoic acid isobutylamide (ii), undeca-2E/Z-ene-
8,10-diyonic acid isobutylamides (iii) and dodec-2-ene-
8,10-diyonic acid isobutylamide (iv) (Figure 2) can induce
CYP3A4 transcription in the same system.
2. Methods
2.1. Chemicals. Hanks’ balanced salt solution (HBSS), foetal
bovine serum (FBS),minimal essential medium alpha with
Glutamax-1 (MEM-α) and hexamer random primers were
all obtained from Invitrogen (Paisley, UK) Rifampicin
HPLC grade, trypsin-EDTA, ethanol, thiazoyl blue tetra-
zolium bromide (MTT) cell culture tested, RNAse-DNAse
free water, dimethylformamide, hydrochloric acid, glacial
acetic acid and sodium dodecyl sulphate were purchased
from Sigma-Aldrich Ltd (Poole, Dorset, UK). Moloney
murine leukemia virus (M-MLV) reverse transcriptase and
reverse transcriptase buﬀer, deoxynucleotide triphosphates
(dNTP) and recombinant RNAsin ribonuclease inhibitor
were obtained from Promega (Southampton, UK) iQ SYBR
G r e e nS u p e r m i xw a sp u r c h a s e df r o mB i o R a dL a b o r a t o r i e s
Inc. (Hertfordshire, UK) and Nucleopsin RNA II kit from
Macherey-Nagel (Abgene, Epson, UK). Primers for β-actin,
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and
CYP3A4 were purchased as high quality, puriﬁed OliGold
Primers from Eurogentec Ltd. (Hampshire, UK) (Table 1).
The alkylamides dodeca-2E,4E,8Z,10E/Z-tetraenoic acid
isobutylamide (1),dodeca-2E,4E-dienoic acid isobutylamide
(2), undeca-2E/Z-ene-8,10-diyonic acid isobutylamides (3)
and dodec-2-ene-8,10-diyonic acid isobutylamide (4)w e r e
purchased from Phytolab GmbH and Co. KG, (Vestenbergs-
greuth, Germany). Echinaforce (batch no: 018451) was a
kind gift from Bioforce, Switzerland.
2.2. Cell Culture. HepG2 cells were a generous gift from Pro-
fessor Ruth Duncan (Cardiﬀ University, UK). HepG2 cells
were routinely cultured in MEM-α supplemented with
Glutamax and 10% FBS, subcultured at ∼70% conﬂuence
and discarded after 10 passages. The cells were kept in a
humidiﬁed 37
◦C incubator with 5% CO2.
2.3. Cell Viability Assay. The thiazoyl blue tetrazolium bro-
mide (MTT) assay was used to determine cell viability. The
assay was performed based on the protocol described by
Hansen et al. [14]. HepG2 cells were seeded at a density of
5000 cells per well in ﬂat bottomed 96-well microtitre plates
(NUNC, Fisher Scientiﬁc, Leicestershire, UK) in 100μlo f
medium and allowed to attach for 48h. The medium was
then removed and replaced with fresh medium containing
the test substance. The ethanol carried over from the extract
or the alkylamide stock solutions was kept below 0.1% to
prevent enzyme denaturation and cytotoxicity. 1:3 serial
dilution series was made from working stock solutions of
the Echinacea extract (Echinaforce) and the alkyalmides. For
Echinaforce two diﬀerent working solutions were prepared:
11.6and64μgmL −1.The11.6μgmL −1 workingsolutionwas
prepared by simply diluting neat Echinaforce with media.
To prepare the 64μgmL −1 working solution, while keeping
the ethanol content below 0.1%, Echinaforce was dried in
a rotary evaporator, freeze dried, re-dissolved in ethanol to
yield a concentration of 85.85mgmL−1 and then diluted to
64μgmL −1 with media. Alkylamide working solutions were
prepared by diluting ethanolic stock solutions to 3μMw i t h
media, keeping ethanol concentration at 0.1%. A solvent
control containing just medium with 0.1% ethanol was
also included. Fresh test substance-containing medium was
added daily for 4 days. Then the medium was removed,
prior to adding 100μl assay media and 20μlM T Ts o l u t i o n
(5mgmL−1 in phosphate buﬀered saline). The plate was
incubated at 37
◦C for 4h before adding 150μl of solubiliza-
tion solution (20% SDS 40% DMF, 2% glacial acetic acid
and 1% vol/vol HCl in distilled water, pH 4.7) and leaving
the plate to develop overnight. Formazan production was
quantiﬁed by determining the absorbance at a wavelength
of 560nm using a plate reader (Labsystems Multiscan, VWR
International).
2.4. Cell Treatment for Induction Studies. 300000 cells
were seeded in 25cm2 tissue culture ﬂasks and left to
adhere for 24h. The medium was then replaced with fresh
mediumcontainingthetest-substance(Echinaforce:22,11.6,Evidence-Based Complementary and Alternative Medicine 3
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Figure 1: The control of CYP protein levels by HMP. Components of the HMP can either bind the AhR and CAR causing their translocation
to the nucleus, or bind the inactive PXR in the nucleus and activate it. Following this binding step, AhR/CAR and PXR can initiate a
sequence of events that increases CYP mRNA production and consequently increased CYP protein production. Increased CYP protein levels
can accelerate drug metabolism, pro-drug activation and bioactivation. CYP3A4 transcription is mainly controlled by PXR. Increase in
mRNA levels can be detected by quantiﬁcation with real time RT-PCR. Another possibility is that HMP components may also aﬀect post
translational modiﬁcations such as ubiquitination, which results in protein degradation. This can lead to a change in CYP protein levels
without aﬀecting mRNA levels.
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Figure 2: Structures of alkylamides assessed for CYP3A4 mRNA expression: (a) dodeca-2E,4 E,8Z,1 0 E/Z-tetraenoic acid isobutylamides
(1),(b)dodeca-2E,4E-dienoic acid isobutylamide (2),(c) undeca-2E/Z-ene-8,10-diyonic acid isobutylamides (3)and(d)dodec-2-ene-8,10-
diyonic acid isobutylamide (4).
1.16μgmL −1, alkylamides: 1.62, 44nM). Rifampicin at a
concentration of 50μM was used as a positive control
for CYP3A4 activation and the solvent control contained
medium with 0.1% ethanol. The test substance containing
medium was prepared by diluting neat Echinaforce, a stock
solution of alkylamide, or a stock solution of rifampicin
directly into the media ensuring that the concentration of
ethanoldid not exceed0.1%.Freshtestsubstance-containing
medium was added daily for 4 days, before RNA isolation for
real-time RT-PCR.
2.5. RNA Isolation. Cells were harvested using trypsin–
EDTA and total RNA was extracted using the Nucleospin
RNA II kit, according to the manufacturer’s instructions.
The RNA was quantiﬁed spectrophotometrically by measur-
ing absorbance (Abs) at 260nm (NanoDrop ND 1000UV4 Evidence-Based Complementary and Alternative Medicine
Table 1: β-actin, GAPDH and CYP3A4 primers.
Gene Gene accession no. Primer Sequence Concentration (nM) Product size
β-Actin X00351 Forward 5 -TCAGCAAGCAGGAGTATG-3  300 97
Reverse 5 -GTCAAGAAAGGGTGTAACG-3  300
GAPDH NM 002046 Forward 5 -TCTCTGCTCCTCCTGTTC-3  900 120
Reverse 5 -GCCCAATACGACCAAATCC-3  900
CYP3A4 NM 017460 Forward 5 -ATCATTGCTGTCTCCAACCTTCAC-3  200 103
Reverse 5 -TGCTTCCCGCCTCAGATTTCTC-3  200
Genebank accession numbers, primer sequences, concentrations and product sizes are shown all genes.
Spectrophotometer).Thepurityoftheﬁnalpreparationswas
determined by calculating the ratios Abs 260/280.
2.6. Reverse Transcription. For each sample, 2.5μgo ft o t a l
RNA was reverse transcribed using M-MLV Reverse Tran-
scriptase according to the manufacturer’s instructions.
Brieﬂy, RNA was diluted to 125ngmL−1, then 7μlo f5 ×
reaction buﬀer, 4μld N T P( 1 0 m Me a c h ) ,1 μl RNase in-
hibitor and 1μl hexamer primers were added to 20μlo f
diluted RNA on ice. The mixture was heated at 65
◦Cf o r
10min and then snap-cooled on ice for 2min, prior to the
addition of 2μl of reverse transcriptase (200 unitsμl−1). The
r e a c t i o nw a sc a r r i e do u ta t4 2
◦C for 90min. The cDNA was
stored at −80
◦C until further use.
2.7. Real-Time PCR. The sequences of the primers used
for real-time PCR are shown in Table 1 along with the
Genebank accession numbers of the cDNA sequences used
for primer design. Primer selection was accomplished by
usingtheBeacondesigner5.1softwaresuite(PremierBiosoft
International,PaloAltoUSA).Theprimerconcentrationwas
optimized to achieve 98–100% ampliﬁcation eﬃciency (data
not shown).
Real-time PCR analysis was carried out using an iCycler
iQ optical system multicolour real-time PCR detection sys-
temwiththeiCycleropticalsystemsoftwareversion3.1(Bio-
rad Laboratories Inc). The samples were prepared by mixing
10μMo fe a c hp r i m e r ,2 5μl2 × iQ SYBR Green Supermix,
2μl of 1:10 diluted cDNA and the appropriate volume of
nuclease-free water. Two 20μl aliquots were used for the
ampliﬁcation reaction. All reactions were run in duplicate.
The hot start polymerase was activated by heating at 95
◦C
for 3min. The cycling conditions were: 0.1min at 95
◦C
(melting) and 0.45min at 55
◦C (annealing and extension).
Threshold values (Ct) were calculated automatically by the
software.
The Ct data was processed according to the method
described by Pfaﬄ [15]. Brieﬂy, the Pfaﬄ equation [15]w a s
ﬁrst used to calculate the relative gene expression ratio, that
is, the change in target gene expression divided by the change
in the reference gene expression.
R =
E
ΔCttarget(Meancontrol−Meantreatment)
target
E
ΔCtreference(Meancontrol−Meantreatment)
reference
,( 1 )
where R is the relative gene expression ratio, E is the
ampliﬁcation eﬃciency (E = 2 at 100% eﬃciency) and ΔCt
is the diﬀerence in threshold (Ct)v a l u e .
Then the R values were normalized with respect to the
vehicle control. Statistical signiﬁcance was determined using
the relative expression software tool (REST), a randomiza-
tion test developed by Pfaﬄ et al. [16].
3. Results
3.1. Determination of Clinically Relevant Concentration
Ranges. Basedontheresultsandpredictionsbyothergroups
[10, 12, 17], we determined that the clinically relevant Echi-
naforce concentration range lies between 1 and 25μgmL −1.
For the alkylamides the clinically relevant concentrations
were taken from Woelkart et al. [18, 19], who found that
alkylamide (1) reached the highest plasma concentration
of 44 or 1.62 nM in human volunteers dosed with an E.
angustifolia root extract and Echinaforce, respectively [18,
19].
3.2.CellViabilityAssay. TheviabilityofHepG2cellsexposed
to Echinaforce (up to 64μgmL −1), ethanol (up to 0.1%)
or each of the alkylamides (up to 3μM), for 96h was
investigated in the MTT assay. No loss of cell viability was
observed.
3.3. Real-Time PCR Analysis. To determine if Echinaforce
and its alkylamides can change the steady-state mRNA levels
of CYP3A4, we exposed HepG2 cells to Echinaforce or
alkylamides over a period of 96h. Rifampicin was used as
the positive control and plain medium with 0.1% ethanol
was used as the vehicle control. Following treatment, the
mRNA was extracted and the levels of CYP3A4 mRNA
were quantiﬁed by real time RT-PCR using β-actin as
the internal control (reference gene). It has been reported
that Echinaforce can up-regulate β-actin in human mono-
cytes/macrophages [12]. Therefore, a second reference gene,
GAPDH,wasusedtodetectβ-actinup-regulation. Wefound
that exposure to Echinaforce (Figure 3) or the alkylamides
(data not shown) did not result in up-regulation of β-
actin expression in HepG2 cells, allowing β-actin to be used
reliably as an internal control. Melt-curve analysis conﬁrmed
the absence of non-speciﬁc ampliﬁcation products (data
now shown). The results of the real time PCR analysis
are shown in Figure 4 and Table 2. Exposure to rifampicinEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Relative CYP3A4 mRNA expression (fold increase over
vehiclecontrol)forβ-actinusingGAPDHasthereferencegene,fol-
lowing treatment of HepG2 cells with Echinaforce (E: 22μgmL −1)
or with vehicle control [0.1% ethanol (EtOH)] for 96h. A value of
1 denotes no increase over the control. The values are the average of
three independent experiments ± SE.
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Figure 4: Relative CYP3A4 mRNA expression (fold increase over
vehicle control) for CYP3A4 in HepG2 cells after a 96 h treatments
with: 50μM rifampicin (R), Echinaforce (E1: 1.16μgmL −1,E 2 :
11.6μgmL −1, E3: 22μgmL −1), alkylamide 1 (1A: 1.62nM, 1B:
40nM), alkylamide 2 (2A: 1.62nM, 2B: 40nM), alkylamide 3 (3A:
1.62nM, 3B: 44nM) and alkylamide 4 (4A: 1.62nM, 4B: 44nM).
A value of 1 denotes no increase over the control. Values are
the average of three independent experiments ± SE. Statistically
signiﬁcant results (P < .05 with a randomization assay) are marked
with ∗∗.
resulted in a statistically signiﬁcant (P < .05) up-regulation
of CYP3A4 expression (3.8-fold) compared to the vehicle
control (0.1% ethanol) as shown in Table 2. In contrast,
exposure to Echinaforce or the alkylamides did not produce
any statistically signiﬁcant changes (at the 5% level) in the
CYP3A4 mRNA levels (see Table 2).
Table 2: Induction of CYP3A4 gene expression in HepG2 cells by
Echinaforce and its alkylamides.
Treatment Concentration Relative CYP3A4
mRNA expression
a (±)S E
Rifampicin 50μM 3.83 1.39
Echinaforce
1.16μgmL −1 1.16 1.03
11.6μgmL −1 1.09 0.44
22μgmL −1 1.08 0.28
Alkylamide 1 1.62nM 1.03 0.69
44nM 1.07 0.19
Alkylamide 2 1.62nM 1.11 0.44
44nM 0.95 0.52
Alkylamide 3 1.62nM 0.98 0.46
44nM 1.11 0.60
Alkylamide 4 1.62nM 1.08 0.22
44nM 0.87 0.34
The cells were treated for 96h, changing the test substance containing
mediumevery24h.Valuesaretheaverageofthreeindependentexperiments
± SE.
aFold increase over the vehicle control.
4. Discussion
This is the ﬁrst study to investigate the inﬂuence of an
Echinacea preparation (Echinaforce) and four alkylamides
on the steady state CYP3A4 mRNA level in HepG2 cells.
No statistically signiﬁcant changes in the mRNA steady-
state level of CYP3A4 were observed after treating the cells
with clinically relevant concentrations of Echinaforce or any
of the alkylamides. In contrast, treatment with rifampicin
resulted in a 3.8-fold up-regulation of CYP3A4. This value
is in agreement with other studies with rifampicin [7,
20]. Therefore, we conclude that the compounds found
in Echinaforce and the alkylamides tested have no eﬀect
on CYP3A4 transcriptional activity in HepG2 cells. It is
possible that Echinaforce or the alkylamides might induce
CYP3A4 expression at higher concentrations than the ones
we tested. However, this would be at levels well above the
clinically relevant range and, thus, would have no practical
signiﬁcance.
The eﬀect of Echinaforce on the induction of other CYP
enzymes has not been investigated and the apparent inability
of Echinaforce to induce CYP3A4 does not imply that this
will be the case for the remaining isoforms. However, due
to the prominent role of CYP3A4 in drug metabolism any
alterationofCYP3A4activityisamajorcontributortoHMP-
drug interactions.
It is important to note that we investigated mRNA
steady-state levels instead of the actual CYP3A4 protein
expression. Therefore, it is not possible to rule out that
Echinaforce might aﬀect the post-translational regulation
of CYP3A4 expression (Figure 1). Several types of post-
translational regulation for CYPs have been documented
including ubiquitination, nitration and phosphorylation
[21];however,wearenotawareofpublishedworksuggesting
that CYP post-translational regulation can be aﬀected by
HMPs.6 Evidence-Based Complementary and Alternative Medicine
Hellum et al. [10] found that two other Echinacea prepa-
rations (Echinagard and Madaus AG) caused a small, but
signiﬁcant suppression of CYP3A4 activity in cultured
primary human hepatocytes. This discrepancy could be the
result of the diﬀerences in methodology. Hellum et al.
[10] exposed the cells to much higher (4–80 times, i.g.,
4.735–473.5μgmL −1) Echinacea purpurea concentrations,
and assayed enzyme activity instead of determining mRNA
levels. We have previously shown [6] that Echinacea prepara-
tions can directly inhibit CYP3A4. Hence, it is possible that
the reduction in CYP3A4 activity observed [10]i sn o ti nf a c t
related to reduced CYP3A4 expression, but rather a direct
inhibitory eﬀect on its enzyme activity. A time course study
would have to be carried out to distinguish between reduced
expression and direct enzyme inhibition.
Although without eﬀect on CYP3A4 mRNA levels, the
Echinacea extract (Echinaforce) concentrations tested here
were suﬃcient to cause observable inhibition of CYP3A4
activity. The IC50 for CYP3A4 inhibition estimated for
Echinacea [6] was 27.2μgmL −1, close to the 22μgmL −1
employed in the present CYP induction study.
HepG2 cells are a human hepatocarcinoma cell line and
thus, they do not exactly mirror the CYP proﬁle present
in the human liver. However, the mechanism controlling
CYP3A4 expression in HepG2 cells are identical to those of
human hepatocytes and thus, if Echinaforce does not induce
CYP3A4in HepG2 cellsit is highly likely thatitwill not do so
in human hepatocytes either. Therefore, overall, our results
suggest that CYP3A4 induction can presumably be excluded
as an avenue for interactions between Echinaforce or its
alkylamides(themajoractiveconstituents)andconventional
medicines thus reducing the risk of adverse eﬀects arising
from such interactions. Overall, this data improves our
understandingofthesafetyproﬁleofEchinacea.Italsoshows
that Echinacea extracts are unlikely to cause cytochrome
P450 mediated interactions with conventional medicines
[22].Thisisinagreementwiththephamacovigilancedata,as
there is a lack of reports documenting interactions between
Echinacea and concurrently used medication.
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